288 related articles for article (PubMed ID: 2952263)
1. Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma.
Boothman DA; Briggle TV; Greer S
Cancer Res; 1987 May; 47(9):2354-62. PubMed ID: 2952263
[TBL] [Abstract][Full Text] [Related]
2. Protective, tumor-selective dual pathway activation of 5-fluoro-2'-deoxycytidine provided by tetrahydrouridine in mice bearing mammary adenocarcinoma-755.
Boothman DA; Briggle TV; Greer S
Cancer Res; 1987 May; 47(9):2344-53. PubMed ID: 2436761
[TBL] [Abstract][Full Text] [Related]
3. Use of 5-fluorodeoxycytidine and tetrahydrouridine to exploit high levels of deoxycytidylate deaminase in tumors to achieve DNA- and target-directed therapies.
Mekras JA; Boothman DA; Perez LM; Greer S
Cancer Res; 1984 Jun; 44(6):2551-60. PubMed ID: 6539164
[TBL] [Abstract][Full Text] [Related]
4. Use of 5-trifluoromethyldeoxycytidine and tetrahydrouridine to circumvent catabolism and exploit high levels of cytidine deaminase in tumors to achieve DNA- and target-directed therapies.
Mekras JA; Boothman DA; Greer SB
Cancer Res; 1985 Nov; 45(11 Pt 1):5270-80. PubMed ID: 2932216
[TBL] [Abstract][Full Text] [Related]
5. Metabolic channeling of 5-fluoro-2'-deoxycytidine utilizing inhibitors of its deamination in cell culture.
Boothman DA; Briggle TV; Greer S
Mol Pharmacol; 1985 May; 27(5):584-94. PubMed ID: 2581125
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor model.
van Laar JA; van der Wilt CL; Rustum YM; Noordhuis P; Smid K; Pinedo HM; Peters GJ
Clin Cancer Res; 1996 Aug; 2(8):1327-33. PubMed ID: 9816304
[TBL] [Abstract][Full Text] [Related]
7. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).
Beumer JH; Parise RA; Newman EM; Doroshow JH; Synold TW; Lenz HJ; Egorin MJ
Cancer Chemother Pharmacol; 2008 Jul; 62(2):363-8. PubMed ID: 17899082
[TBL] [Abstract][Full Text] [Related]
8. Incorporation of 5-fluorodeoxycytidine and metabolites into nucleic acids of human MCF-7 breast carcinoma cells.
Kaysen J; Spriggs D; Kufe D
Cancer Res; 1986 Sep; 46(9):4534-8. PubMed ID: 2425957
[TBL] [Abstract][Full Text] [Related]
9. Selective activation of 5'-deoxy-5-fluorouridine by tumor cells as a basis for an improved therapeutic index.
Armstrong RD; Diasio RB
Cancer Res; 1981 Dec; 41(12 Pt 1):4891-4. PubMed ID: 6171343
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice.
Beumer JH; Eiseman JL; Parise RA; Joseph E; Holleran JL; Covey JM; Egorin MJ
Clin Cancer Res; 2006 Dec; 12(24):7483-91. PubMed ID: 17138702
[TBL] [Abstract][Full Text] [Related]
11. Alteration of fluorouracil metabolism in human colon cancer cells by dipyridamole with a selective increase in fluorodeoxyuridine monophosphate levels.
Grem JL; Fischer PH
Cancer Res; 1986 Dec; 46(12 Pt 1):6191-9. PubMed ID: 2946402
[TBL] [Abstract][Full Text] [Related]
12. Metabolism and mechanism of action of 5-fluorodeoxycytidine.
Newman EM; Santi DV
Proc Natl Acad Sci U S A; 1982 Nov; 79(21):6419-23. PubMed ID: 6959127
[TBL] [Abstract][Full Text] [Related]
13. Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells.
Ren Q; Van Groeningen CJ; Hardcastle A; Aherne GW; Geoffroy F; Allegra CJ; Johnston PG; Grem JL
Oncol Res; 1997; 9(2):77-88. PubMed ID: 9167189
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo radiation sensitization by the halogenated pyrimidine 5-chloro-2'-deoxycytidine.
Russell KJ; Rice GC; Brown JM
Cancer Res; 1986 Jun; 46(6):2883-7. PubMed ID: 3698014
[TBL] [Abstract][Full Text] [Related]
15. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of potentiation of antitumor activity of 5-fluoro-2'-deoxyuridine in the adenocarcinoma 755 system by guanosine 5'-monophosphate.
Iigo M; Yamaizumi Z; Nakajima Y; Nishimura S; Hoshi A
Drugs Exp Clin Res; 1988; 14(4):257-63. PubMed ID: 2458897
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of 5-[
Yu HM; Chiu CH; Chen WT; Wu CH; Lin PY; Huang YY; Chen JH; Tzen KY; Shiue CY; Lin WJ
Appl Radiat Isot; 2019 Jun; 148():152-159. PubMed ID: 30959352
[TBL] [Abstract][Full Text] [Related]
18. Combinations of tetrahydrouridine and cytosine arabinoside in mouse tumors.
Kreis W; Hession C; Soricelli A; Scully K
Cancer Treat Rep; 1977 Oct; 61(7):1355-64. PubMed ID: 589601
[TBL] [Abstract][Full Text] [Related]
19. Selective accumulation of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine (FdUrd-C8) and sustained release of its active metabolites in VX-2 rabbit hepatoma following intraarterial administration of FdUrd-C8 solution in Lipiodol.
Kawaguchi T; Fukushima S; Hayashi Y; Kaneko M; Nakano M
Cancer Res; 1988 Aug; 48(15):4179-83. PubMed ID: 2839289
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral injection of thymidine: enhancement of the antitumor activity and incorporation of 5-fluorouracil into tumor RNA in a murine tumor system.
Matsuoka H; Masuda H; Maehara Y; Sugimachi K; Inokuchi K
Cancer Treat Rep; 1986 Jul; 70(7):851-7. PubMed ID: 3719577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
